Wayfinding Financial, LLC Abb Vie Inc. Transaction History

Wayfinding Financial, LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 09, 2024	SELL	$154.79 - $180.76 $5,572 - $6,507	-36 Reduced 0.54%	6,656 $1.14 Million
Q1 2024 May 09, 2024	BUY	$159.82 - $182.1 $24,452 - $27,861	153 Added 2.34%	6,692 $1.22 Million
Q4 2023 Jan 09, 2024	BUY	$137.6 - $154.97 $2,614 - $2,944	19 Added 0.29%	6,539 $1.01 Million
Q3 2023 Nov 02, 2023	BUY	$133.59 - $154.65 $15,630 - $18,094	117 Added 1.83%	6,520 $971,000
Q2 2023 Jul 31, 2023	SELL	$132.51 - $164.9 $21,201 - $26,384	-160 Reduced 2.44%	6,403 $862,000
Q1 2023 May 04, 2023	BUY	$144.61 - $166.54 $79,969 - $92,096	553 Added 9.2%	6,563 $1.05 Million
Q4 2022 Feb 09, 2023	SELL	$138.31 - $165.87 $36,237 - $43,457	-262 Reduced 4.18%	6,010 $817,000
Q3 2022 Nov 08, 2022	BUY	$134.21 - $153.93 $2,818 - $3,232	21 Added 0.34%	6,272 $841,000
Q2 2022 Aug 09, 2022	BUY	$137.62 - $174.96 $412 - $524	3 Added 0.05%	6,251 $957,000
Q1 2022 May 09, 2022	BUY	$131.98 - $163.75 $31,411 - $38,972	238 Added 3.96%	6,248 $954,000
Q4 2021 Jan 28, 2022	BUY	$107.43 - $135.93 $645,654 - $816,939	6,010 New	6,010 $817,000

3,853

1.25B

16.8M

12.2M

Ticker ABBV
Exchange NYSE
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,768,099,968
Market Cap $318B
Description
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheuma...

Get notified when there are updates to the investment portfolio of Wayfinding Financial, LLC, based on Form 13F filings with the SEC.

Stay updated on Wayfinding Financial, LLC with notifications on news.